Intelligence Feed event · Policy · 2026-09-12

    Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A

    Question

    Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A

    Direct answer

    Eli Lilly reported that its Immunology business segment generated $2.6 billion in net sales during the first half of 2026, representing 9% top-line growth year-over-year and contributing 6.1% of aggregate firm revenues. The division's expansion relies on anchor product Taltz, commercial rollouts of Ebglyss and Omvoh, and acquired assets from DICE, Morphic, and Merida. The portfolio buildout establishes an operational growth engine alongside its metabolic and GLP-1 commercial lines.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-revenue-rises-9-in-h1-2026-to-2-6b-on-dice-and-morphic-m-a-67a43e

    POLICY
    Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A
    Eli Lilly reported that its Immunology business segment generated $2.6 billion in net sales during the first half of 2026, representing 9% top-line growth year-over-year and contributing 6.1% of aggregate firm revenues. The division's expansion relies on anchor product Taltz, commercial rollouts of Ebglyss and Omvoh, and acquired assets from DICE, Morphic, and Merida. The portfolio buildout establishes an operational growth engine alongside its metabolic and GLP-1 commercial lines.
    LLY
    Impact
    62
    SEP 12
    SIG
    85%
    LLY
    Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A
    Eli Lilly reported that its Immunology business segment generated $2.6 billion in net sales during the first half of 2026, representing 9% top-line growth year-over-year and contributing 6.1% of aggregate firm revenues. The division's expansion relies on anchor product Taltz, commercial rollouts of Ebglyss and Omvoh, and acquired assets from DICE, Morphic, and Merida. The portfolio buildout establishes an operational growth engine alongside its metabolic and GLP-1 commercial lines.
    → Acquired immunology pipelines from DICE, Morphic, and Merida drive $2.6 billion in H1 revenue, reducing Eli Lilly's concentration risk on GLP-1 drug franchises.
    Impact
    Eli Lilly reported that its Immunology business segment generated $2.6 billion in net sales during the first half of 2026, representing 9% top-line growth year-over-year and contributing 6.1% of aggregate firm revenues. The division's expansion relies on anchor product Taltz, commercial rollouts of Ebglyss and Omvoh, and acquired assets from DICE, Morphic, and Merida. The portfolio buildout establishes an operational growth engine alongside its metabolic and GLP-1 commercial lines.
    Affected
    LLY
    Transmission
    Acquired immunology pipelines from DICE, Morphic, and Merida drive $2.6 billion in H1 revenue, reducing Eli Lilly's concentration risk on GLP-1 drug franchises.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYrevenue diversification via immunology M&A integrationUp1-3mImmunology revenue generated $2.6B in H1 2026 (+9% YoY) via DICE, Morphic, and Merida acquisitions.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month